Research Links Popular Joint Supplement to Faster Alzheimer’s Progression

Analysis of health records covering millions of individuals has uncovered a potential association between the commonly used joint supplement glucosamine and an accelerated progression from mild cognitive impairment to dementia, prompting fresh worries about its safety profile.

In this observational research, which looked at both prescription and over‑the‑counter glucosamine consumption in people diagnosed with mild cognitive impairment, researchers discovered that participants who consistently reported using the supplement faced roughly a 25 percent higher chance of developing Alzheimer’s‑type dementia during the follow‑up interval compared with non‑users, after controlling for age, sex, cardiovascular risk factors and other typical medications.

Laboratory investigations presented together with the epidemiological data indicate that glucosamine could intensify a pathological mechanism called O‑GlcNAcylation—an irregular addition of sugar residues to neuronal proteins—that has been linked to the creation of toxic amyloid plaques and tau tangles typical of Alzheimer’s disease.

Derived from shellfish shells or manufactured synthetically, glucosamine ranks among the top‑selling dietary supplements for osteoarthritis and joint discomfort, generating sales that top billions of dollars each year across the United States and Europe. Historically, it has been viewed as low‑risk, with only a handful of serious adverse events noted in joint‑health clinical trials.

Although these results do not prove causation, they encourage doctors and consumers to balance possible cognitive hazards against the joint‑health advantages. The research team intends to launch prospective trials to verify the link and to examine if dosage, formulation, or length of use modify the observed impact. Meanwhile, health practitioners should talk about the new evidence with patients who already have memory issues and keep an eye on cognitive shifts in those taking glucosamine.